Literature DB >> 9294127

Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.

O J Cohen1, M Vaccarezza, G K Lam, B F Baird, K Wildt, P M Murphy, P A Zimmerman, T B Nutman, C H Fox, S Hoover, J Adelsberger, M Baseler, J Arthos, R T Davey, R L Dewar, J Metcalf, D J Schwartzentruber, J M Orenstein, S Buchbinder, A J Saah, R Detels, J Phair, C Rinaldo, J B Margolick, G Pantaleo, A S Fauci.   

Abstract

HIV-1-infected long-term nonprogressors are a heterogeneous group of individuals with regard to immunologic and virologic markers of HIV-1 disease. CC chemokine receptor 5 (CCR5) has recently been identified as an important coreceptor for HIV-1 entry into CD4+ T cells. A mutant allele of CCR5 confers a high degree of resistance to HIV-1 infection in homozygous individuals and partial protection against HIV disease progression in heterozygotes. The frequency of CCR5 heterozygotes is increased among HIV-1- infected long-term nonprogressors compared with progressors; however, the host defense mechanisms responsible for nonprogression in CCR5 heterozygotes are unknown. We hypothesized that nonprogressors who were heterozygous for the mutant CCR5 gene might define a subgroup of nonprogressors with higher CD4+ T cell counts and lower viral load compared with CCR5 wild-type nonprogressors. However, in a cohort of 33 HIV-1-infected long-term nonprogressors, those who were heterozygous for the mutant CCR5 gene were indistinguishable from CCR5 wild-type nonprogressors with regard to all measured immunologic and virologic parameters. Although epidemiologic data support a role for the mutant CCR5 allele in the determination of the state of long-term nonprogression in some HIV-1- infected individuals, it is not the only determinant. Furthermore, long-term nonprogressors with the wild-type CCR5 genotype are indistinguishable from heterozygotes from an immunologic and virologic standpoint.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294127      PMCID: PMC508340          DOI: 10.1172/JCI119682

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  59 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

Review 3.  Host genetics and infectious disease.

Authors:  D J Weatherall
Journal:  Parasitology       Date:  1996       Impact factor: 3.234

4.  Identification of multiple and distinct CD8+ T cell suppressor activities: dichotomy between infected and uninfected individuals, evolution with progression of disease, and sensitivity to gamma irradiation.

Authors:  T D Barker; D Weissman; J A Daucher; K M Roche; A S Fauci
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

5.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

6.  Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.

Authors:  M Loetscher; T Geiser; T O'Reilly; R Zwahlen; M Baggiolini; B Moser
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

7.  Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection.

Authors:  R A Kaslow; M Carrington; R Apple; L Park; A Muñoz; A J Saah; J J Goedert; C Winkler; S J O'Brien; C Rinaldo; R Detels; W Blattner; J Phair; H Erlich; D L Mann
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

8.  Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure.

Authors:  W A Paxton; S R Martin; D Tse; T R O'Brien; J Skurnick; N L VanDevanter; N Padian; J F Braun; D P Kotler; S M Wolinsky; R A Koup
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

9.  Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.

Authors:  D C Montefiori; G Pantaleo; L M Fink; J T Zhou; J Y Zhou; M Bilska; G D Miralles; A S Fauci
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

10.  Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.

Authors:  S M Wolinsky; B T Korber; A U Neumann; M Daniels; K J Kunstman; A J Whetsell; M R Furtado; Y Cao; D D Ho; J T Safrit
Journal:  Science       Date:  1996-04-26       Impact factor: 47.728

View more
  11 in total

1.  Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis.

Authors:  Julian J Lum; Oren J Cohen; Zilin Nie; Joel G Weaver; Timothy S Gomez; Xiao-Jian Yao; David Lynch; André A Pilon; Nanci Hawley; John E Kim; Zhaoxia Chen; Michael Montpetit; Jaime Sanchez-Dardon; Eric A Cohen; Andrew D Badley
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

2.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

3.  Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.

Authors:  Florian Hladik; Huanliang Liu; Emily Speelmon; Devon Livingston-Rosanoff; Sean Wilson; Polachai Sakchalathorn; Yon Hwangbo; Benjamin Greene; Tuofu Zhu; M Juliana McElrath
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins.

Authors:  H M Naif; S Li; M Alali; J Chang; C Mayne; J Sullivan; A L Cunningham
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 5.  Immunodeficiency lentiviral infections in natural and non-natural hosts.

Authors:  Jason M Brenchley; Mirko Paiardini
Journal:  Blood       Date:  2011-04-19       Impact factor: 22.113

6.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors:  S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

7.  Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection.

Authors:  Gurvinder Kaur; Michael Tuen; Diana Virland; Sandra Cohen; Narinder K Mehra; Christian Münz; Sayed Abdelwahab; Alfredo Garzino-Demo; Catarina E Hioe
Journal:  Virology       Date:  2007-09-04       Impact factor: 3.616

8.  CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32.

Authors:  O J Cohen; S Paolucci; S M Bende; M Daucher; H Moriuchi; M Moriuchi; C Cicala; R T Davey; B Baird; A S Fauci
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

10.  Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

Authors:  Dawn A Maier; Andrea L Brennan; Shuguang Jiang; Gwendolyn K Binder-Scholl; Gary Lee; Gabriela Plesa; Zhaohui Zheng; Julio Cotte; Carmine Carpenito; Travis Wood; S Kaye Spratt; Dale Ando; Philip Gregory; Michael C Holmes; Elena E Perez; James L Riley; Richard G Carroll; Carl H June; Bruce L Levine
Journal:  Hum Gene Ther       Date:  2013-03-06       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.